600513 联环药业
已收盘 06-05 15:00:00
资讯
新帖
简况
医保局发布医保目录调整方案；内蒙古检查售卖集采药违规药店
21世纪经济报道 · 06-01
医保局发布医保目录调整方案；内蒙古检查售卖集采药违规药店
每周股票复盘：联环药业（600513）股东户数下降13.63%，研发投入达3.26亿
证券之星 · 05-31
每周股票复盘：联环药业（600513）股东户数下降13.63%，研发投入达3.26亿
联环药业(600513)5月25日股东户数4.27万户，较上期减少13.63%
证券之星 · 05-29
联环药业(600513)5月25日股东户数4.27万户，较上期减少13.63%
联环药业(600513.SH)：凝胶剂通过药品GMP符合性检查
智通财经 · 05-29
联环药业(600513.SH)：凝胶剂通过药品GMP符合性检查
联环药业（600513）发布2025年年度股东会决议公告，5月28日股价下跌0.51%
证券之星 · 05-28
联环药业（600513）发布2025年年度股东会决议公告，5月28日股价下跌0.51%
每周股票复盘：联环药业（600513）LH-1801片拟6-7月报产
证券之星 · 05-24
每周股票复盘：联环药业（600513）LH-1801片拟6-7月报产
联环药业（600513）披露召开2025年度暨2026年第一季度业绩说明会公告，5月20日股价下跌1.17%
证券之星 · 05-20
联环药业（600513）披露召开2025年度暨2026年第一季度业绩说明会公告，5月20日股价下跌1.17%
联环药业（600513）披露LH-1801片Ⅲ期临床数据及NDA申报计划，5月18日股价下跌2.14%
证券之星 · 05-18
联环药业（600513）披露LH-1801片Ⅲ期临床数据及NDA申报计划，5月18日股价下跌2.14%
联环药业最新公告：控股子公司获维生素B12注射液药品补充申请批准通知书
证券之星 · 05-11
联环药业最新公告：控股子公司获维生素B12注射液药品补充申请批准通知书
每周股票复盘：联环药业（600513）LH-1801片Ⅲ期临床主要终点符合预期
证券之星 · 05-10
每周股票复盘：联环药业（600513）LH-1801片Ⅲ期临床主要终点符合预期
联环药业（600513）披露1类新药LH-1801片Ⅲ期单药临床试验揭盲结果，5月8日股价下跌3.14%
证券之星 · 05-08
联环药业（600513）披露1类新药LH-1801片Ⅲ期单药临床试验揭盲结果，5月8日股价下跌3.14%
每周股票复盘：联环药业（600513）Q1营收增29.14%
证券之星 · 05-02
每周股票复盘：联环药业（600513）Q1营收增29.14%
联环药业(600513)3月31日股东户数4.94万户，较上期增加4.14%
证券之星 · 04-28
联环药业(600513)3月31日股东户数4.94万户，较上期增加4.14%
图解联环药业一季报：第一季度单季净利润同比下降72.14%
证券之星 · 04-28
图解联环药业一季报：第一季度单季净利润同比下降72.14%
股市必读：联环药业年报 - 第四季度单季净利润同比下降640.94%
证券之星 · 04-22
股市必读：联环药业年报 - 第四季度单季净利润同比下降640.94%
诺和诺德与OpenAI达成战略合作；再生元牵手Telix
21世纪经济报道 · 04-15
诺和诺德与OpenAI达成战略合作；再生元牵手Telix
联环药业(600513.SH)：盐酸甲氧氯普胺注射液获得药品注册证书
智通财经 · 04-14
联环药业(600513.SH)：盐酸甲氧氯普胺注射液获得药品注册证书
每周股票复盘：联环药业（600513）近5日3次登上龙虎榜
证券之星 · 04-12
每周股票复盘：联环药业（600513）近5日3次登上龙虎榜
4月7日联环药业（600513）龙虎榜数据
证券之星 · 04-07
4月7日联环药业（600513）龙虎榜数据
每周股票复盘：联环药业（600513）因换手率及涨幅两度登龙虎榜
证券之星 · 04-05
每周股票复盘：联环药业（600513）因换手率及涨幅两度登龙虎榜
加载更多
公司概况
公司名称：
江苏联环药业股份有限公司
所属行业：
医药制造业
上市日期：
2003-03-19
主营业务：
江苏联环药业股份有限公司的主营业务是药品生产、销售，化工原料、药品批发、药品等研发，技术成果转让、咨询。公司的主要产品是泌尿系统药、抗组胺药、心血管药、甾体激素、抗生素。公司是国家高新技术企业、国家知识产权示范企业、江苏省工业互联网发展示范企业（标杆工厂类）。
发行价格：
7.88
{"stockData":{"symbol":"600513","market":"SH","secType":"STK","nameCN":"联环药业","latestPrice":16.68,"timestamp":1780642801000,"preClose":17,"halted":0,"volume":9581019,"delay":0,"changeRate":-0.0188,"floatShares":285000000,"shares":285000000,"eps":-0.4028,"marketStatus":"已收盘","change":-0.32,"latestTime":"06-05 15:00:00","open":17.25,"high":17.28,"low":16.55,"amount":161000000,"amplitude":0.0429,"askPrice":16.69,"askSize":232,"bidPrice":16.68,"bidSize":150,"shortable":0,"etf":0,"ttmEps":-0.4028,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780882200000},"marketStatusCode":5,"adr":0,"adjPreClose":17,"symbolType":"stock","openAndCloseTimeList":[[1780623000000,1780630200000],[1780635600000,1780642800000]],"highLimit":18.7,"lowLimit":15.3,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":285456270,"isCdr":false,"pbRate":3.72,"roa":"--","roe":"0.5%","epsLYR":-0.34,"committee":0.211236,"marketValue":4761000000,"turnoverRate":0.0336,"status":1,"floatMarketCap":4761000000},"requestUrl":"/m/hq/s/600513/","defaultTab":"news","newsList":[{"id":"2640981365","title":"医保局发布医保目录调整方案；内蒙古检查售卖集采药违规药店","url":"https://stock-news.laohu8.com/highlight/detail?id=2640981365","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640981365?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:01","pubTimestamp":1780272073,"startTime":"0","endTime":"0","summary":"药械审批国家医保局发布2026年国家医保目录调整工作方案5月31日，国家医保局发布《2026年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整工作方案》《2026年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整申报指南》《谈判药品续约规则》以及《非独家药品竞价规则》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606013755285483.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606013755285483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","BK0251","BK0060","IPOS","301263","600521","BK0239","BK0114","BK0028","BK0070","BK0188","BK0012","301096","600513","BK0196","BK0250","BK0096","BK0201","BK0187","BK0185","BK0109","BK0216","600196","BK0175","300562"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639604651","title":"每周股票复盘：联环药业（600513）股东户数下降13.63%，研发投入达3.26亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2639604651","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639604651?lang=zh_cn&edition=full","pubTime":"2026-05-31 03:09","pubTimestamp":1780168150,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，联环药业报收于17.58元，较上周的18.93元下跌7.13%。本周，联环药业5月25日盘中最高价报19.12元。业绩披露要点：2025年研发投入3.26亿元，LH-1801项目完成III期临床试验。股本股东变化截至2026年5月25日，公司股东户数为4.27万户，较3月31日减少6735.0户，减幅13.63%。户均持股数量由5779.0股增至6691.0股，户均持股市值为12.37万元。截至2026年5月25日，股东总数为42,663户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100000865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639626571","title":"联环药业(600513)5月25日股东户数4.27万户，较上期减少13.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639626571","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639626571?lang=zh_cn&edition=full","pubTime":"2026-05-29 17:51","pubTimestamp":1780048304,"startTime":"0","endTime":"0","summary":"证券之星消息，近日联环药业披露，截至2026年5月25日公司股东户数为4.27万户，较3月31日减少6735.0户，减幅为13.63%。在化学制药行业个股中，联环药业股东户数高于行业平均水平，截至5月25日，化学制药行业平均股东户数为3.56万户。从股价来看，2026年3月31日至2026年5月25日，联环药业区间跌幅为33.87%，在此期间股东户数减少6735.0户，减幅为13.63%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900033351.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639625335","title":"联环药业(600513.SH)：凝胶剂通过药品GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2639625335","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639625335?lang=zh_cn&edition=full","pubTime":"2026-05-29 17:06","pubTimestamp":1780045610,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联环药业(600513.SH)发布公告，近日，公司收到江苏省药品监督管理局签发的《药品GMP符合性检查告知书》。此次检查的范围为凝胶剂[四车间，C4厂房凝胶剂生产线(配制、灌装、热合工序)、B2厂房凝胶剂生产线(灭菌、灯检、包装工序)]，检查结论为符合要求。公司此次通过药品GMP符合性检查，表明公司凝胶剂生产线符合药品GMP要求，为满足相关药品的市场需求奠定了坚实基础。上述事项对公司目前经营业绩不会产生重大影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447765.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638694535","title":"联环药业（600513）发布2025年年度股东会决议公告，5月28日股价下跌0.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638694535","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638694535?lang=zh_cn&edition=full","pubTime":"2026-05-28 22:42","pubTimestamp":1779979338,"startTime":"0","endTime":"0","summary":"截至2026年5月28日收盘，联环药业报收于17.51元，较前一交易日下跌0.51%，最新总市值为49.98亿元。该股当日开盘17.6元，最高17.94元，最低17.21元，成交额达1.36亿元，换手率为2.72%。近日，江苏联环药业股份有限公司发布《2025年年度股东会决议公告》。涉及关联交易的议案已按规定回避表决。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800043474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637837349","title":"每周股票复盘：联环药业（600513）LH-1801片拟6-7月报产","url":"https://stock-news.laohu8.com/highlight/detail?id=2637837349","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637837349?lang=zh_cn&edition=full","pubTime":"2026-05-24 02:45","pubTimestamp":1779561912,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，联环药业报收于18.93元，较上周的20.05元下跌5.59%。本周，联环药业5月19日盘中最高价报20.28元。本周关注点公司公告汇总：LH-1801片拟于2026年6-7月完成pre-NDA沟通并提交申报。江苏联环药业股份有限公司召开2025年年度股东会，审议董事会工作报告、财务决算与预算、利润分配、日常关联交易预计、董事薪酬、银行授信等议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636282341","title":"联环药业（600513）披露召开2025年度暨2026年第一季度业绩说明会公告，5月20日股价下跌1.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636282341","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636282341?lang=zh_cn&edition=full","pubTime":"2026-05-20 22:21","pubTimestamp":1779286879,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，联环药业报收于19.43元，较前一交易日下跌1.17%，最新总市值为55.46亿元。该股当日开盘19.68元，最高19.82元，最低19.23元，成交额达1.8亿元，换手率为3.25%。近日，联环药业发布《关于召开2025年度暨2026年第一季度业绩说明会的公告》。公告显示，公司将于2026年5月28日10:00-11:00通过上证路演中心召开业绩说明会，以视频播放结合网络文字互动方式举行。投资者可于2026年5月21日至5月27日16:00前通过上证路演中心网站或公司邮箱提交问题。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000043332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636071257","title":"联环药业（600513）披露LH-1801片Ⅲ期临床数据及NDA申报计划，5月18日股价下跌2.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636071257","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636071257?lang=zh_cn&edition=full","pubTime":"2026-05-18 22:10","pubTimestamp":1779113412,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，联环药业报收于19.62元，较前一交易日下跌2.14%，最新总市值为56.01亿元。该股当日开盘20.01元，最高20.01元，最低19.53元，成交额达2.24亿元，换手率为4.0%。近日，联环药业发布投资者关系活动记录表。公司就LH-1801片的研发进展、临床数据、市场竞争、上市计划及商业化策略等问题进行了回应。LH-1801片为SGLT-2抑制剂，已完成与达格列净的头对头Ⅲ期临床试验，数据显示其在降糖、代谢指标及潜在心肾保护方面表现良好，安全性较高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800037154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634404980","title":"联环药业最新公告：控股子公司获维生素B12注射液药品补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2634404980","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634404980?lang=zh_cn&edition=full","pubTime":"2026-05-11 17:22","pubTimestamp":1778491354,"startTime":"0","endTime":"0","summary":"联环药业(600513.SH)公告称，公司控股子公司常乐制药近日收到国家药监局核准签发的关于维生素B12注射液(1ml:0.5mg/1ml:1mg)《药品补充申请批准通知书》，批准变更药品处方及生产工艺等事项，并增加1ml:1mg规格，通过仿制药质量和疗效一致性评价。该药品主要用于巨幼细胞性贫血及神经炎的辅助治疗。2025年度全终端医院销售额为8004.93万元，研发投入约294万元。本次获批预计不会对近期经营业绩产生重大影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100023812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634571411","title":"每周股票复盘：联环药业（600513）LH-1801片Ⅲ期临床主要终点符合预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2634571411","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634571411?lang=zh_cn&edition=full","pubTime":"2026-05-10 01:24","pubTimestamp":1778347452,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，联环药业报收于21.57元，较上周的22.78元下跌5.31%。本周，联环药业5月6日盘中最高价报24.2元。公司公告汇总：LH-1801片20mg与40mg组HbA1c降幅显著优于安慰剂组，P值均<0.0001。公司公告汇总：联合用药试验显示LH-1801片疗效不劣于达格列净。公司公告汇总联环药业关于公司1类新药LH-1801片Ⅲ期单药临床试验揭盲结果的公告江苏联环药业股份有限公司1类新药LH-1801片Ⅲ期单药临床试验已完成揭盲，主要终点符合预期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633439553","title":"联环药业（600513）披露1类新药LH-1801片Ⅲ期单药临床试验揭盲结果，5月8日股价下跌3.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633439553","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633439553?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:16","pubTimestamp":1778231788,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，联环药业报收于21.57元，较前一交易日下跌3.14%，最新总市值为61.57亿元。该股当日开盘23.5元，最高23.6元，最低21.55元，成交额达9.47亿元，换手率为14.84%。公司于近日披露《关于公司1类新药LH-1801片Ⅲ期单药临床试验揭盲结果的公告》。联合用药试验亦显示疗效不劣于达格列净。LH-1801片上市时间、市场竞争及商业化进程存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800030535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632641317","title":"每周股票复盘：联环药业（600513）Q1营收增29.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632641317","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632641317?lang=zh_cn&edition=full","pubTime":"2026-05-02 02:09","pubTimestamp":1777658951,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，联环药业报收于22.78元，较上周的20.21元上涨12.72%。本周，联环药业4月30日盘中最高价报23.3元。联环药业当前最新总市值65.03亿元，在化学制药板块市值排名86/150，在两市A股市值排名2842/5200。股本股东变化股东户数变动截至2026年3月31日，联环药业股东户数为4.94万户，较2025年12月31日增加1963.0户，增幅4.14%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200000368.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630374868","title":"联环药业(600513)3月31日股东户数4.94万户，较上期增加4.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630374868","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630374868?lang=zh_cn&edition=full","pubTime":"2026-04-28 17:32","pubTimestamp":1777368768,"startTime":"0","endTime":"0","summary":"证券之星消息，近日联环药业披露，截至2026年3月31日公司股东户数为4.94万户，较12月31日增加1963.0户，增幅为4.14%。在化学制药行业个股中，联环药业股东户数高于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.57万户。从股价来看，2025年12月31日至2026年3月31日，联环药业区间涨幅为52.7%，在此期间股东户数增加1963.0户，增幅为4.14%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800051345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630129003","title":"图解联环药业一季报：第一季度单季净利润同比下降72.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630129003","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630129003?lang=zh_cn&edition=full","pubTime":"2026-04-28 03:58","pubTimestamp":1777319900,"startTime":"0","endTime":"0","summary":"证券之星消息，联环药业2026年一季报显示，一季度公司主营收入8.11亿元，同比上升29.14%；归母净利润642.48万元，同比下降72.14%；扣非净利润561.16万元，同比下降74.67%；负债率59.39%，投资收益-22.58万元，财务费用871.28万元，毛利率26.52%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800011128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629059143","title":"股市必读：联环药业年报 - 第四季度单季净利润同比下降640.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629059143","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629059143?lang=zh_cn&edition=full","pubTime":"2026-04-22 01:11","pubTimestamp":1776791462,"startTime":"0","endTime":"0","summary":"来自：联环药业2025年归母净利润亏损9833.24万元，同比下降216.84%。2025年第四季度单季度主营收入6.29亿元，同比增长22.01%；单季度归母净利润亏损6327.03万元，同比下降640.94%；单季度扣非净利润亏损5505.18万元，同比下降35.7%。联环药业关于公司2025年度日常关联交易执行情况及2026年度日常关联交易预计的公告2025年度公司与非同一控制下关联方实际发生关联交易金额为1,580.62万元，与同一控制下关联方实际发生金额为5,255.09万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200002859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627045478","title":"诺和诺德与OpenAI达成战略合作；再生元牵手Telix","url":"https://stock-news.laohu8.com/highlight/detail?id=2627045478","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627045478?lang=zh_cn&edition=full","pubTime":"2026-04-15 08:01","pubTimestamp":1776211308,"startTime":"0","endTime":"0","summary":"政策动向国家医疗保障局持续开展定点医药机构违法违规使用医保基金自查自纠工作国家医疗保障局近日在全国范围内组织开展2026年定点医药机构违法违规使用医保基金自查自纠工作。自查自纠聚焦重点领域“逐渐细化、持续深化”。在既往心血管内科、骨科、血液净化、康复、医学影像、临床检验、肿瘤、麻醉、重症医学等9个重点领域的基础上，本年度进一步将口腔、内分泌、精神医学3个领域纳入自查自纠范围。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705224747.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705224747.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4599","IE00BZ1G4Q59.USD","301087","BK4588","NVOH","NVO","BK4007","300558","BK4585","NVOX","LU1093756325.SGD","002437","02196","600196","688177","LU1093756168.USD","BK4532","IE00BKVL7J92.USD","REGN","600513","LU0154236417.USD","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627194334","title":"联环药业(600513.SH)：盐酸甲氧氯普胺注射液获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2627194334","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627194334?lang=zh_cn&edition=full","pubTime":"2026-04-14 16:59","pubTimestamp":1776157175,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联环药业 发布公告，公司控股子公司新乡市常乐制药有限责任公司于近日收到国家药品监督管理局核准签发的关于盐酸甲氧氯普胺注射液的《药品注册证书》。2025年前三季度全国医院盐酸甲氧氯普胺注射液销售额达6,624.45万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"联环药业(600513.SH)：盐酸甲氧氯普胺注射液获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626124162","title":"每周股票复盘：联环药业（600513）近5日3次登上龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2626124162","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626124162?lang=zh_cn&edition=full","pubTime":"2026-04-12 01:10","pubTimestamp":1775927419,"startTime":"0","endTime":"0","summary":"截至2026年4月10日收盘，联环药业报收于22.57元，较上周的27.68元下跌18.46%。本周，联环药业4月7日盘中最高价报27.79元。4月10日盘中最低价报22.55元。联环药业当前最新总市值64.43亿元，在化学制药板块市值排名86/150，在两市A股市值排名2824/5196。此次是近5个交易日内第3次上榜。沪深交易所2026年4月7日公布的交易公开信息显示，联环药业因有价格涨跌幅限制的日收盘价格跌幅偏离值达到7%的前五只证券登上龙虎榜。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200000114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625179936","title":"4月7日联环药业（600513）龙虎榜数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2625179936","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625179936?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:14","pubTimestamp":1775553280,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年4月7日公布的交易公开信息显示，联环药业因有价格涨跌幅限制的日收盘价格跌幅偏离值达到7%的前五只证券登上龙虎榜。此次是近5个交易日内第2次上榜。截至2026年4月7日收盘，联环药业报收于24.96元，下跌9.83%，换手率22.29%，成交量63.63万手，成交额16.59亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700024145.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600513","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625615903","title":"每周股票复盘：联环药业（600513）因换手率及涨幅两度登龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2625615903","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625615903?lang=zh_cn&edition=full","pubTime":"2026-04-05 01:08","pubTimestamp":1775322490,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，联环药业报收于27.68元，较上周的25.61元上涨8.08%。本周，联环药业4月2日盘中最高价报32.27元，股价触及近一年最高点。本周关注点来自交易信息汇总：联环药业因日换手率达20%及三日涨幅偏离值累计达20%两度登上龙虎榜。交易信息汇总联环药业于2026年4月1日因有价格涨跌幅限制的日换手率达到20%进入龙虎榜，为近5个交易日内第2次上榜。截至公告日，常乐制药对该药品研发投入约541.60万元，2026年已获3个生产批件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780862492863,"stockEarnings":[{"period":"1week","weight":-0.0512},{"period":"1month","weight":-0.286},{"period":"3month","weight":-0.2639},{"period":"6month","weight":-0.0855},{"period":"1year","weight":0.7417},{"period":"ytd","weight":-0.089}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0318},{"period":"3month","weight":-0.0234},{"period":"6month","weight":0.032},{"period":"1year","weight":0.1902},{"period":"ytd","weight":0.0148}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏联环药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"42663人(较上一季度减少13.63%)","perCapita":"6690股","listingDate":"2003-03-19","address":"江苏省扬州市邗江区生物健康产业园健康一路9号","registeredCapital":"28545万元","survey":" 江苏联环药业股份有限公司的主营业务是药品生产、销售，化工原料、药品批发、药品等研发，技术成果转让、咨询。公司的主要产品是泌尿系统药、抗组胺药、心血管药、甾体激素、抗生素。公司是国家高新技术企业、国家知识产权示范企业、江苏省工业互联网发展示范企业（标杆工厂类）。","listedPrice":7.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"联环药业(600513)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供联环药业(600513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"联环药业,600513,联环药业股票,联环药业股票老虎,联环药业股票老虎国际,联环药业行情,联环药业股票行情,联环药业股价,联环药业股市,联环药业股票价格,联环药业股票交易,联环药业股票购买,联环药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"联环药业(600513)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供联环药业(600513)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}